BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) Treatment
RESEARCH TRIANGLE PARK, N.C. Feb. 23, 2024 - In a groundbreaking announcement, BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) revealed new analyses of real-world usage of ORLADEYO (berotralstat), an oral, once-daily treatment for hereditary angioedema (HAE). These analyses highlight the remarkable reduction in attack rates experienced by patients who embarked on ORLADEYO therapy, regardless of the severity of their disease, history of prior prophylaxis, or their C1-inhibitor (C1-INH) level and function. The encouraging findings uncover a potential breakthrough in the management of HAE, bringing hope to those affected by this rare and debilitating condition.
HAE is a rare genetic disorder characterized by unpredictable and recurrent attacks of swelling in various body parts, including the hands, feet, face, and abdomen. These attacks can be painful, disfiguring, and potentially life-threatening, impacting the physical, emotional, and social well-being of patients. Historically, HAE management has relied on acute treatments and prophylactic measures, aiming to prevent and reduce the occurrence of attacks. However, the availability of a long-term, once-daily oral treatment like ORLADEYO represents a significant advancement and a potential game-changer in the field.
The real-world data presented by BioCryst Pharmaceuticals, Inc. have shed light on the tangible benefits experienced by patients who initiated ORLADEYO treatment. Over a comprehensive 18-month period, these patients witnessed rapid, substantial, and sustained reductions in HAE attack rates. Remarkably, these positive outcomes were consistent across patients, irrespective of the severity of their condition, prior prophylactic measures, or the level and function of their C1-INH - a key protein responsible for the regulation of inflammation.
Such encouraging real-world data provide substantial evidence regarding the efficacy and reliability of ORLADEYO. These findings demonstrate that this innovative treatment goes beyond simply managing the symptoms of HAE but also has the potential to transform the lives of patients by significantly reducing the frequency and severity of attacks. By targeting the underlying cause of HAE, ORLADEYO tackles the condition at its root, offering newfound hope for those afflicted by this challenging disease.
Notably, the 18-month duration of the study provides valuable insights into the sustainability of ORLADEYO’s impact. The sustained reductions in attack rates witnessed throughout the analysis further cement the potential of this groundbreaking treatment to offer long-term relief and stability to patients, allowing them to regain control of their lives and minimize the disruptive impact of HAE.
The real-world implications of these findings are significant. Patients suffering from HAE can now look forward to a tangible solution that tackles the root cause of their condition and provides them with a much-needed respite from the unpredictable and distressing attacks. Furthermore, the availability of ORLADEYO as a once-daily oral treatment simplifies the management of HAE, offering patients a convenient option that integrates seamlessly into their daily routines.
In conclusion, the unveiling of real-world data showcasing the rapid, substantial, and sustained reductions in HAE attack rates with ORLADEYO treatment is a major breakthrough. This transformative therapy has the potential to revolutionize the management of HAE, providing renewed hope and a better quality of life for patients. With further research and continued development, ORLADEYO could pave the way for improved treatment options and greater relief for individuals affected by this rare genetic disorder.
To know more about the study, please refer to the press release by BioCryst Pharmaceuticals, Inc. available at: link to the article
Comments